Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Ann Plast Surg. 2016 Aug;77(2):217–222. doi: 10.1097/SAP.0000000000000584

TABLE 2.

Treatment Characteristics for Patients in the Combined and Surgical Cohorts

Combined Cohort (n = 11) Surgical Cohort (n = 10) P
Operative management
 No. debridements
  Mean (range)   2.3 (1–4)   2.6 (1–3) 0.71
 Defect size, cm2
  Mean (range)    56 (24–225) 48.5 (18–90) 0.49
 Negative pressure (VAC) therapy (%)    21 (72)    18 (60) 0.89
 Interval from excision to DPC, d
  Mean (range)   4.1 (2–10)   4.2 (2–12) 0.76
Biologic therapy
 Infliximab/Ustekinumab   8/3   N/A
 Time from closure to initiation of biologic therapy, d
  Mean (range)    16 (14–20)   N/A
 Duration of biologic therapy, mo
  Mean (range) 10.5 (6–15)*   N/A
Follow-up, mo
 Mean (range)    18 (6–31) 20.5 (4–36) 0.81
*

Four patients remained on biologic therapy at the time of final follow-up. DPC indicates delayed primary closure; N/A, Not Applicable, VAC, vacuum-assisted closure.

HHS Vulnerability Disclosure